EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Intracoronary stenting without coumadin: One month results of a French multicenter study

Marie C. Morice, Gilles Zemour, Edgar Benveniste, Yves Biron, Claude Bourdonnec, René Faivre, Jean Fajadet, Philippe Gaspard, Bernard Glatt, Patrick Joly, Pierre Labrunie, Yves Lienhart, Jean Marco, Pierre Y. Petiteau, Thierry Royer, Bernard Valeix

Catheterization and Cardiovascular Diagnosis · 1995-05 · 35 (1) · 1-7

DOI: 10.1002/ccd.1810350102 ↗
AbstractBibliografische Angaben

Abstract

Abstract In order to simplify post‐coronary stenting treatment and to obtain a lower rate of complications, especially in bailout situations, seven French institutions treated 246 stented patients with 0.25 g/day of ticlopidine, 0.1 g/day of IV aspirin, and 2 days of heparin followed by low‐molecular‐weight heparin for 1 month. Fifty percent of patients had a planned stenting procedure, and 50% had an unplanned procedure, including 29 (11.8%) in bailout situations. Subacute occlusion occurred in three (1.2%) patients (one death, two non‐Q‐wave infarctions). During the 1 month follow‐up period, another death was reported (non‐stent‐related), two elective coronary artery bypass grafts were performed, and three additional patients presented with non‐Q‐wave myocardial infarctions. Nine (3.7%) patients had a groin complication that required blood transfusion or surgical repair. These results suggest that while waiting for the technological advancements of stents, postprocedural treatment that includes a low dosage of ticlopidine, aspirin, and low‐molecular‐weight heparin is a very effective alternative to conventional poststenting therapy. © 1995 Wiley‐Liss, Inc.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →